Membrane-type matrix metalloproteinase-1 (MT1-MMP) is down-regulated in estrogen-deficient rat osteoblast in vivo

Journal of Endocrinological Investigation

Volumn 27, Issue 1, 2004, Pages 1-5

  Liao, E Y ^a   Liao, H J ^a   Guo, L J ^a   Zhou, H D ^a   Wu, X P ^a   Dai, R C ^a   Luo, Xianghang H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Estrogen; Matrix metalloproteinase; Osteoblast

Indexed keywords

ESTRADIOL; ESTROGEN; GELATINASE A; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOWN REGULATION; ENZYME INDUCTION; ENZYME SYNTHESIS; ESTROGEN DEFICIENCY; FEMALE; FEMUR HEAD; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; MEDICAL DOCUMENTATION; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SAMPLING;

EID: 1542376111     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350902     Document Type: Article

References (21)

1. Turner RT, Riggs BL, Spelsberg TC. Skeletal effects of estrogen. Endocr Rev 1994, 16: 275-300.
2. Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus HG. Expression of metalloproteinase and tissue inhibitor of metalloptroteinase in human osteoblast-like cells: metalloproteinase biosythesis. Endocrinology 1994, 134: 213-21.
3. Sato H, Takino T, Okada Y, Cao J. et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994, 370: 61-5.
4. Westermarck J, Kahari V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13: 781-92.
5. D'Ortho MP, Will H, Atklnson S, et al. Membrane-type matrix metalloproteinase 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997, 250: 751-7.
6. Liao EY, Luo XH, Deng XG, Wu XP. Effects of 17b-estradiol on the expression of nembrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human osteoblastic MG-63cell cultures. J Endocrinol Invest 2001, 24: 876-81.
7. Zuker S, Drews M, Conner C. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase (MT1 -MMP). J Biol Chem 1998, 273: 1216-22.
8. Kanayma HO, Yokota KY, Kurokawa Y, Murakami Y, Nishitani M, Kagwa S. Prognostic values of matrix metalloproteinase and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998, 82: 1359-66.
9. Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000, 275: 26411-5.
10. Ko YC, Langley KE, Mendiaz EA, Parker VP, Taylor SM, DeClerck YA. The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity. Biochem Biophys Res Commun 1997, 236: 100-5.
11. Emmert-Buck MR, Emonard HP, Corcoran ML, Foidart JM, Stetler-Stevenson WG. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995, 364: 28-32.
12. Imai K, Ohuchi E, Aoki T, et al. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinase 2. Cancer Res 1996, 56: 2707-10.
13. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. J Biol Chem 1996, 271: 17119-23
14. Pei D, Weiss SJJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem 1996, 271: 9135-40.
15. Gilles C, Polette M, Coraux C et al. Contribution of MT1-MMP and of human laminin-5 γ2 chain degradation to mammary epithelial cell migration. J Cell Sci 2001, 114: 2967-76
16. Quaranta V. Cell migration through extracellular matrix: membrane-type metalloproteinases make the way. J Cell Biol 2000, 149: 1167-70.
17. McClelland P, Onyia JE, Miles RR, et al. Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. J Cell Biochem 1998, 70: 391-401.
18. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99: 81-92.
19. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature. 1994, 370: 555-7.
20. McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994, 370: 558-61.
21. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332: 305-11